Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator-activated receptor α ligand in rats

In Vivo

Volumn 16, Issue 2, 2002, Pages 145-152

  Rao, M Sambasiva ^a   Papreddy, Kashireddy ^a   Musunuri, Srinidhi ^a   Okonkwo, Adaora ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Choline deficiency; Fatty acid oxidation; Fatty change; Peroxisome proliferators; Steatohepatitis

Indexed keywords

AMINOTRANSFERASE; CHOLINE; CIPROFIBRATE; FATTY ACID; LIGAND; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; CELL RECEPTOR; CLOFIBRIC ACID; DRUG DERIVATIVE; TRANSCRIPTION FACTOR;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG POTENCY; ELECTRON MICROSCOPY; FATTY ACID OXIDATION; GENE TARGETING; HEPATITIS; LIVER CELL; LIVER DISEASE; LIVER LOBECTOMY; MALE; METASTASIS; MORPHOLOGY; NONHUMAN; NORMAL VALUE; ORGAN DONOR; POSTOPERATIVE COMPLICATION; RAT; RISK ASSESSMENT; STEATOSIS; UNITED STATES; ANIMAL; BODY WEIGHT; FATTY LIVER; FISCHER 344 RAT; LIVER; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; VITAMIN DEFICIENCY;

ANIMALS; ANTILIPEMIC AGENTS; BODY WEIGHT; CHOLINE DEFICIENCY; CLOFIBRIC ACID; FATTY LIVER; LIGANDS; LIVER; MALE; ORGAN SIZE; RATS; RATS, INBRED F344; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0035984958     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Liver transplantation: Expanding the donor pool
2. Liver transplantation
3. Living related liver transplantation in adults
4. 157 adult to adult living donor liver transplantation
5. Liver resection for colorectal metastasis
6. Dynamics of normal and injured human liver regeneration after hepatectomy as assessed on the basis of computed tomography and liver function
7. The outcome of steatotic grafts in liver transplantation
8. Fatty liver in liver transplantation and surgery
9. Hepatic steatosis as a potential risk factor for major hepatic resection
10. Failure of regeneration of the steatotic rat liver: Disruption at two different levels in the regeneration pathway
11. The effect of microvesicular fatty change on liver regeneration after partial hepatectomy
12. Regeneration of liver with marked fatty change following partial hepatectomy in rats
13. Cell and tissue adaptation to injury
14. Diagnosis and interpretation of steatosis and steatohepatitis
15. Biochemical aspects of fatty liver
16. Alcoholic liver disease
17. Inhibition of mitochondrial β-oxidation as a mechanism of hepatotoxicity
18. Peroxisomal P-oxidation and steatoliepatitis
19. Nonalcoholic steatohepatitis: Another disease of affluence
20. Alcoholic liver disease: New insights in pathogenesis lead to new treatments
21. Hepatic steatosis: Innocent bystander or guilty party?
22. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease
23. Metabolic and nutritional consideration in nonalcoholic fatty liver
24. Varying body mass index cutoff points to describe overweight prevalence among U.S. adults. NHANES111 (1988-1994)
25. Prevalence of and risk factors for hepatic steatosis in Northern Italy
26. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors
27. Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans
28. Peroxisome proliferator-induced plelotropic responses: Pursuit of a phenomenon
29. Peroxisome proliferators and cytochrome P-450A induction
30. Peroxisome proliferator-activated receptors: Finding the orphan a home
31. Peroxisome proliferator activated receptors, orphans with ligands and functions
32. Peroxisome proliferator activated receptor-a expression in human liver
33. Roles of PPARs in health and disease
34. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-111
35. Choline deficiency, lipotrope deficiency and the development of liver disease including liver cancer: A new perspective
36. Effect of dexamethasone on ciprofibrate induced cell proliferation and peroxisome proliferation
37. Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme. A oxidase gene
38. Peroxisomal and mitochondrial fatty acid β-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor cc and peroxisomal fatty acyl-CoA oxidase
39. Expression of peroxisomal enoyl-CoA 17 hydrogenase/3-hydroxyacyl CoA dehydrogenase enzyme and its mRNA in peroxisome proliferator-induced liver tumors
40. Animal models of steatosis
41. Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis
42. Comparison of constitutive and inducible levels of expression of peroxisomal β-oxidation and catalase genes in liver and extrahepatic tissues of rat
43. Etiopathogenesis of nonalcoholic steatohepatitis
44. Increased hepatocyte CYP2E I expression in a rat nutritional model of hepatic steatosis with inflammation
45. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis
46. Metformin reverses fatty liver disease in obese, leptin-deficient mice
47. Fatty liver - An additional and treatable feature of the insulin resistance syndrome
48. Bezafibrate for tamoxifen-induced nonalcoholic steatohepatitis
49. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
50. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: A pilot study
51. Hepatic effects of dietary weight loss in morbidly obese patients
52. Treatment of nonalcoholic fatty liver: Present and emerging therapies